WOMEN’S REPRODUCTIVE CANCERS Women’s reproductive cancers (including ovarian, endometrial, uterine, and cervical) are massively underfunded given their deadly toll, and as a result, remain particularly challenging to treat. Over
in the 100,000 women United States are diagnosed each year, and
32,000 Over
women die annually from them
Taking into account incidence and mortality,
ovarian cancer receives
19x less funding than prostate cancer
70%
of ovarian cancer patients are diagnosed at late stages, and these patients have a
29.2%
5-year survival rate
NYSCF Women’s Reproductive Cancers Initiative driving a new paradigm in how these cancers are studied and treated We are creating personalized models of cancer to capture the uniqueness of each patient’s disease from their own cells, helping us design targeted and effective therapies.
Guiding this Initiative is a Scientific Advisory Board of world-leading cancer physicians and researchers. Current members include: Michael Birrer, MD, PhD
Carol Aghajanian, MD
Memorial Sloan Kettering Cancer Center
The University of Alabama at Birmingham
Ronny Drapkin, MD, PhD
Susan M. Domchek, MD
University of Pennsylvania
Carla Grandori, MD, PhD
University of Pennsylvania
University of Pennsylvania
SEngine Precision Medicine
Kathleen Moore, MD University of Oklahoma
Elizabeth M. Swisher, MD University of Washington
Carl June, MD
Siddhartha Mukherjee, MD, DPhil Columbia University Medical Center
Victor Velculescu, MD, PhD Johns Hopkins University
Oliver Zivanovic, MD, PhD
Memorial Sloan Kettering Cancer Center
George Coukos, MD, PhD
University of Lausanne
Olivier Elemento, PhD
Weill Cornell Medicine
Ursula Matulonis, MD
Dana-Farber Cancer Institute
Alessandro Santin, MD Yale Cancer Center
Irving Weissman, MD
Stanford University